African Bundibugyo Ebolavirus Vaccine Candidate to Be Advanced to Clinical Trials

African Bundibugyo ebolavirus vaccine candidate to be advanced to clinical trials

Leading African biopharmaceutical company Minapharm Group (www.Minapharm.com), headquartered in Egypt with subsidiaries in Berlin, will receive up to US$16.5 million from the Coalition for Epidemic Preparedness Innovations (CEPI) to advance the development of a Bundibugyo ebolavirus vaccine candidate, strengthening efforts to develop vaccines to combat the fastest-growing and second-largest Ebola outbreak on record affecting the Democratic Repub…

CEPI backs Minapharm's experimental Ebola vaccine with up to $16.5 ...

Ebolavirus vaccine nears African clinical trials as Gavi commits $7m more funding

Leading African biopharmaceutical company Minapharm Group, headquartered in Egypt with subsidiaries in Berlin, will receive up to $16.5 million from the Coalition for Epidemic Preparedness Innovations (CEPI) to advance the development of a Bundibugyo ebolavirus vaccine candidate, strengthening efforts to develop vaccines to combat the fastest-growing and second-largest Ebola outbreak on record affecting the Democratic […] The post Ebolavirus vac…

Ebolavirus vaccine candidate advances to clinical trials

African biopharmaceutical company Minapharm Group, headquartered in Egypt with subsidiaries in Berlin, will receive up to $16,5-million from the Coalition for Epidemic Preparedness Innovations (CEPI) to advance the development of a Bundibugyo ebolavirus vaccine candidate. Minapharm’s Bundibugyo vaccine is designed by ProBioGen, a Berlin-based specialist within Minapharm Group, based on their proprietary modified vaccinia Ankara (MVA) vaccine pla…

Berlin-developed Ebola vaccine heads toward African trial - European Biotechnology Magazine

The Coalition for Epidemic Preparedness Innovations (CEPI) is providing Egyptian biopharmaceutical company Minapharm with up to $16.5 million (€14 million) to advance another vaccine candidate against Bundibugyo Ebola virus into clinical development. The candidate was developed by Minapharm’s Berlin-based subsidiary ProBioGen using its proprietary MVA-CR19 platform. A Phase I trial is planned in Africa, with the broader aim of helping the contin…